These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23763243)

  • 1. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
    Ma C; Armstrong AW
    J Dermatolog Treat; 2014 Oct; 25(5):401-8. PubMed ID: 23763243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous melanoma: new advances in treatment.
    Foletto MC; Haas SE
    An Bras Dermatol; 2014; 89(2):301-10. PubMed ID: 24770508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targets in the treatment of advanced melanoma: new first-line treatment options.
    Culos KA; Cuellar S
    Ann Pharmacother; 2013 Apr; 47(4):519-26. PubMed ID: 23548648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
    Copley-Merriman C; Stevinson K; Liu FX; Wang J; Mauskopf J; Zimovetz EA; Chmielowski B
    Medicine (Baltimore); 2018 Aug; 97(31):e11736. PubMed ID: 30075584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

  • 9. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
    Banaszynski M; Kolesar JM
    Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
    J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
    Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the skin toxicities from new melanoma drugs.
    Mavropoulos JC; Wang TS
    Curr Treat Options Oncol; 2014 Jun; 15(2):281-301. PubMed ID: 24867225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.
    Ludlow SP; Pasikhova Y
    Melanoma Res; 2013 Dec; 23(6):496-7. PubMed ID: 24025700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
    Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
    Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib and cutaneous adverse events--report of five cases.
    Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
    An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.